Q-omics provides the consensus-scored RPL5P8 profile across patient tissues and cancer cell-line models. RPL5P8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL5P8 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPL5P8 RNA expression shows 12,287 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where RPL5P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL5P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL5P8 survival associations across molecular data types. RPL5P8 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL5P8 RNA expression–survival associations across cancer types. High RPL5P8 expression shows unfavorable associations in ACC, KICH and STAD, but favorable associations in UCEC, KIRC and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL5P8 RNA expression.
This table summarizes RPL5P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL5P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL5P8 shows lower tumor expression in KIRP and BLCA and higher tumor expression in COAD, KIRC and LUAD. The COAD box plot shows higher RPL5P8 RNA expression in tumor versus normal tissue (log2 FC = +0.278, t-test p = .001).
This table shows molecular features associated with RPL5P8 in patient tissues and cancer cell lines. In patient samples, RPL5P8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
